Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Retatrutide is the unimolecular triple agonist furthest in development and data from phase 2 trials suggests that this may soon become the most potent weight-lowering pharmacotherapy to be licenced
& Gzel, A
As always, when starting any new medication, it is important to go over the risks, benefits and targets so that you can understand if a medication is right for you
Many of these involved dosing errors where patients administered five to twenty times more than intended
There are no brand name medicines that lower total medical cost over a population, and generally health economists believe that drugs that cost less than $100,000 or $150,000 per QALY are high value. Implications for employers: The net cost of GLP-1 drugs is already just 42% of the list price, so a 50% list price cut might not lead to employer savings
US$ 22.63
US$ 27.21
US$ 25.55
US$ 28.56
